HIV-Tat dependent chemotaxis and invasion, key aspects of Tat mediated pathogenesis Authors
Cite this article as: Vené, R., Benelli, R., Noonan, D. et al. Clin Exp Metastasis (2000) 18: 533. doi:10.1023/A:1011991906685 Abstract
Extracellular Tat acts as a pleiotropic molecule inducing several biological effects on different target cells. Tat stimulates the chemotaxis of numerous cell types and it appears to have oncogenic activities, including acting as a co-factor for Kaposi's sarcoma. The Tat protein has been shown to bind integrins through an RGD amino acid motif. Tat is an angiogenic factor able to induce the migration and invasion of endothelial and KS cells through the interaction of its basic domain with the VEGF receptor VEGFR2 (Flk-1/KDR). We have also found that Tat is able to mimic chemokines, activating monocyte migration through the `chemokine like' cysteine-core domain. Tat is a chemoattractant for dendritic cells, and both the RGD and basic domains appear to be involved in this response. In a recent study we demonstrated that Tat is chemotactic for PMN and induces Ca
2+ mobilization in vitro. Experiments using synthetic peptides showed that Tat activities on PMN are mediated by the `chemokine like' region. Finally Tat is also able to induce B cell chemotaxis, while its activity on helper T cells has not yet been clarified. Here we review data on Tat-dependent chemotaxis and discuss the possible implications in Tat mediated pathogenesis. chemokine chemotaxis HIV Tat VEGF
This revised version was published online in July 2006 with corrections to the Cover Date.
Gatignol A, Jeang K-T. Tat as a transcriptional activator and a potential therapeutic target for HIV-1. In Jean K-T (ed): HIV-1: Molecular Biology and Pathogenesis. San Diego, California: Academic Press 2000; 209–27
Lotz M, Clark LI, Ganu V. HIV-1 transactivator protein Tat induces proliferation and TGF beta expression in human articular chondrocytes. J Cell Biol 1994; 124(3): 365–71.
Westendorp MO et al. Human immunodeficiency virus type 1 Tat upregulates interleukin-2 secretion in activated T cells. J Virol 1994; 68(7): 4177–85.
Scala G et al. The expression of the interleukin 6 gene is induced by the human immunodeficiency virus 1 TAT protein. J Exp Med 1994; 179(3): 961–71.
Buonaguro L et al. Effects of the human immunodeficiency virus type 1 Tat protein on the expression of inflammatory cytokines. J Virol 1992; 66(12): 7159–67.
Buonaguro L et al. The human immunodeficiency virus type 1 Tat protein transactivates tumor necrosis factor beta gene expression through a TAR-like structure. J Virol 1994; 68(4): 2677–82.
Sastry K et al. HIV-1 tat gene induces tumor necrosis factor-beta (lymphotoxin) in a human B-lymphoblastoid cell line. J Biol Chem 1990; 265: 20091–3.
Howcroft TK et al Repression of MHC class I gene promoter activity by two-exon Tat of HIV. Science1993; 260(5112): 1320–2.
Taylor J et al. Activation of expression of genes coding for extracellular matrix protein in Tat-producing glioblastoma cells. Proc Natl Acad Sci USA 1992; 89: 9617–21.
Longo F et al. A novel approach to protein-protein interaction: complex formation between the p53 tumor suppressor and the HIV Tat proteins. Biochem Biophys Res Commun 1995; 206(1): 326–34.
Garcia JA et al. Functional domains required for tat-induced transcriptional activation of the HIV-1 long terminal repeat. EMBO J 1988; 7: 3143–7.
Brake D, Debouck C, Biesecker G. Identification of an Arg-Gly-Asp (RGD) cell adhesion site in human immunodeficiency virus type 1 transactivation protein, tat. J Cell Biol 1990; 111: 1275–81.
Ensoli B et al. Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J Virol 1993; 67(1): 277–87.
Frankel AD, Pabo CO. Cellular uptake of the tat protein from human immunodeficiency virus. Cell 1988; 55: 1189–93.
Barillari G et al. The Tat protein of human immunodeficiency virus type 1, a growth factor for AIDS Kaposi sarcoma and cytokineactivated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RGD amino acid sequence. Proc Natl Acad Sci USA 1993; 90(17): 7941–5.
Mitola S et al. Tat-human immunodeficiency virus-1 induces human monocyte chemotaxis by activation of vascular endothelial growth factor receptor-1. Blood 1997; 90: 1365–72.
Albini A et al. The angiogenesis induced by HIV-1 Tat is mediated by the flk-1/KDR receptor on vascular endothelial cells. Nat Med 1996; 2(12): 1371–5.
Albini A et al. HIV-1 Tat protein mimicry of chemokines. Proc Natl Acad Sci USA 1998; 95(22): 13153–8.
Ghezzi S et al. Inhibition of CXCR4-dependent HIV-1 infection by extracellular HIV-1 Tat. Biochem Biophys Res Commun 2000; 270(3): 992–6.
Gutheil WG et al. Human immunodeficiency virus 1 Tat binds to dipeptidyl aminopeptidase IV (CD26): A possible mechanism for Tat's immunosuppressive activity. Proc Natl Acad Sci USA 1994; 91(14): 6594–8.
Noonan DM, Albini A. From the outside in: extracellular activities of HIV Tat. In Jeang K-T (ed): HIV-1: Molecular Biology and Pathogenesis. San Diego, California: Academic Press 2000; 229–50.
Kim CM et al. The HIV tat gene transforms human keratinocytes. Oncogene 1992; 7(8): 1525–9.
Corallini A et al. Systemic expression of HIV1 tat gene in transgenic mice induces endothelial proliferation and tumors of different histotypes. Cancer Res 1993; 53: 5569–75.
Corallini A et al. Promotion of tumor metastases and induction of angiogenesis by native HIV-1 Tat protein from BK virus/tat transgenic mice. AIDS 1996; 10: 701–10.
Kundu RK et al. Expression of the human immunodeficiency virus-Tat gene in lymphoid tissues of transgenic mice is associated with B-cell lymphoma. Blood 1999; 94(1): 275–82.
Albini A et al. Angiogenic potential in vivo by Kaposi sarcoma cellfree supernatants and HIV1-tat product: Inhibition of KS-like lesions by TIMP-2. AIDS 1994; 8: 1237–44.
Albini A et al. Angiogenic properties of human immunodeficiency virus type 1 Tat protein. Proc Natl Acad Sci USA 1995; 92: 4838–42.
Ensoli B et al. Synergy between basic fibroblast growth factor and HIV-1 tat protein in induction of Kaposi's sarcoma. Nature 1994; 371: 674–80.
Albini A et al. HIV-tat protein is a heparin-binding angiogenic growth factor. Oncogene 1996; 12: 289–97.
Ganju RK et al. Human immunodeficiency virus tat modulates the Flk-1/KDR receptor, mitogen-activated protein kinases, and components of focal adhesion in Kaposi's sarcoma cells. J Virol 1998; 72(7): 6131–7.
Montaldo F et al. Expression of functional tyrosine kinases on immortalized Kaposi's sarcoma cells. J Cell Physiol 2000; 184(2): 246–54.
Morini M et al. Kaposi's Sarcoma Cells of Different Etiologic Origins Respond to HIV-Tat through the Flk-1/KDR (VEGFR-2): Relevance in AIDS-KS Pathology. Biochem Biophys Res Commun 2000; 273(1): 267–71.
Arese M et al. HIV-1 Tat protein stimulates
vascular permeability and lymphomononuclear cell recruitment. J Immunol 2001; 166(2): 1380–8.
Falcioni R et al. Alpha 6 beta 4 and alpha 6 beta 1 integrins associate with erbB-2 in human carcinoma cell lines. Exp Cell Res 1997; 236(1): 76–85.
Soldi R et al. Role of
3 integrin in the activation of vascular endothelial growth factor receptor-2. Embo J 1999; 18(4): 882–92.
Barillari G et al. The Tat protein of human immunodeficiency virus type-1 promotes vascular cell growth and locomotion by engaging the
3 integrins and by mobilizing sequestered basic fibroblast growth factor. Blood 1999; 94(2): 663–72.
Biancone L et al. Motility induced by human immunodeficiency virus-1 tat on Kaposi's sarcoma cells requires platelet-activating factor synthesis. Am J Pathol 1999; 155(5): 1731–9.
Del Sorbo L et al. Tat-induced platelet-activating factor synthesis contributes to the angiogenic effect of HIV-1 Tat. Eur J Immunol 2001;: 31(2): 376–83.
Benelli R et al. Monocyte-derived dendritic cells and monocytes migrate to HIV-Tat RGD and basic peptides. AIDS 1998; 12: 261–8.
Zocchi MR, Poggi A, Rubartelli A. The RGD-containing domain of exogenous HIV-1 Tat inhibits the engulfment of apoptotic bodies by Dendritic cells. AIDS 1997; 11: 1227–35.
Lafrenie RM et al. HIV-1-Tat modulates the function of monocytes and alters their interactions with microvessel endothelial cells. A mechanism of HIV pathogenesis. J Immunol 1996; 156(4): 1638–45.
Lafrenie RM et al. HIV-1-Tat protein promotes chemotaxis and invasive behavior by monocytes. J Immunol 1996; 157(3): 974–7.
Albini A et al. Identification of a novel domain of HIV Tat involved in monocyte chemotaxis. J Biol Chem 1998; 273: 15895–900.
Brodie SJ et al. HIV-specific cytotoxic T lymphocytes traffic to lymph nodes and localize at sites of HIV replication and cell death. J Clin Invest 2000; 105(10): 1407–17.
Roulston A et al. Regulation of human immunodeficiency virus type 1 and cytokine gene expression in myeloid cells by NF-kappa B/Rel transcription factors. Microbiol Rev 1995; 59(3): 481–505.
Park IW, Wang JF, Groopman JE. HIV-1 Tat promotes monocyte chemoattractant protein-1 secretion followed by transmigration of monocytes. Blood 2001; 97(2): 352–8.
Kutsch O et al. Induction of the chemokines interleukin-8 and IP-10 by human immunodeficiency virus type 1 tat in astrocytes. J Virol 2000; 74(19): 9214–21.
Del Sorbo L et al. The synthesis of platelet-activating factor modulates chemotaxis of monocytes induced by HIV-1 Tat. Eur J Immunol 1999; 29(5): 1513–21.
Xiao H et al. Selective CXCR4 antagonism by tat: implications for
expansion of coreceptor use by HIV-1. Proc Natl Acad Sci USA 2000; 97(21): 11466–71.
Benelli R et al. Human immunodeficiency virus transactivator protein (Tat) stimulates chemotaxis, calcium mobilization, and activation of human polymorphonuclear leukocytes: Implications for Tat-mediated pathogenesis. J Infect Dis 2000; 182(6): 1643–51.
Prakash O et al. The human immunodeficiency virus type I Tat protein potentiates ethanol-induced neutrophil functional impairment in transgenic mice. Alcohol Clin Exp Res 1998; 22(9): 2043–9.
de Paulis A et al. Tat protein is an HIV-1-encoded
-chemokine homolog that promotes migration and up-regulates CCR3 expression on human Fc
RI(+) cells. J Immunol 2000; 165(12): 7171–9.
Rappaport J et al. Molecular pathway involved in HIV-1-induced CNS pathology: Role of viral regulatory protein, Tat. J Leuk Biol 1999; 65(4): 458–65.
Philippon V et al. The basic domain of the lentiviral Tat protein is responsible for damages in mouse brain: Involvement of cytokines. Virology 1994; 205(2): 519–29.
Hegg CC et al. Beta-chemokines and human immunodeficiency virus type-1 proteins evoke intracellular calcium increases in human microglia. Neuroscience 2000; 98(1): 191–9.
Vogel J et al. The HIV tat gene induces dermal lesions resembling Kaposi's sarcoma in transgenic mice. Nature 1988; 335(13): 606–11.
Chirivi RG et al. Human immunodeficiency virus-1 (HIV-1)-Tat protein promotes migration of acquired immunodeficiency syndromerelated lymphoma cells and enhances their adhesion to endothelial cells. Blood 1999; 94(5): 1747–54.
Shutt DC, Soll DR. HIV-induced T-cell syncytia release a two component T-helper cell chemoattractant composed of Nef and Tat. J Cell Sci 1999; 112(Pt 22): 3931–41.
Fiorelli V et al. IFN-gamma induces endothelial cells to proliferate and to invade the extracellular matrix in response to the HIV-1 Tat protein: Implications for AIDS-Kaposi's sarcoma pathogenesis. J Immunol 1999. 162(2): 1165–70.
Prakash O et al. Human Kaposi's sarcoma cell-mediated tumorigenesis in human immunodeficiency type 1 tat-expressing transgenic mice. J Natl Cancer Inst 2000; 92(9): 721–8.
Kumar A et al. Human immunodeficiency virus-1-tat induces matrix metalloproteinase-9 in monocytes through protein tyrosine phosphatase-mediated activation of nuclear transcription factor NFkappaB. FEBS Lett 1999; 462(1-2): 140–4.
Johnston JB et al. HIV-1 Tat neurotoxicity is prevented by matrix metalloproteinase inhibitors. Ann Neurol 2001; 49(2): 230–41.
Bayer P et al. Structural studies of HIV-1 Tat protein. J Mol Biol 1995; 247(4): 529–35.
Rubartelli A, Sitia R. Secretion of mammalian proteins that lack a signal sequence. In Kuchler K, Rubartelli A and Holland B (eds): Unusual Secretory Pathways: From Bacteria to Man. Heidelberg: Springer-Verlag 1997; 87–114.
© Kluwer Academic Publishers 2000